

# Sequence Analysis and Domain Motifs in the Porcine Skin Decorin Glycosaminoglycan Chain<sup>\*[5]</sup>

Received for publication, November 19, 2012, and in revised form, January 28, 2013. Published, JBC Papers in Press, February 19, 2013, DOI 10.1074/jbc.M112.437236

Xue Zhao<sup>‡§</sup>, Bo Yang<sup>§</sup>, Kemal Solakylidirim<sup>§</sup>, Eun Ji Joo<sup>§</sup>, Toshihiko Toida<sup>¶</sup>, Kyohei Higashi<sup>¶</sup>, Robert J. Linhardt<sup>§||\*\*††</sup>, and Lingyun Li<sup>§1</sup>

From the <sup>‡</sup>College of Food Science and Technology, Ocean University of China, Qingdao 266003, China, the Departments of <sup>§</sup>Chemistry and Chemical Biology, <sup>¶</sup>Chemical and Biological Engineering, <sup>\*\*</sup>Biology, and <sup>††</sup>Biomedical Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York 12180, and the <sup>¶</sup>Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan

**Background:** GAG of decorin is important, but its structural motifs and sequences are unknown.

**Results:** FT-MS has mapped domains, and a small GAG chain was sequenced.

**Conclusion:** GAG chain structure varies depending on origin, but motif structure appears relatively consistent and may be comprised of a small number of sequences.

**Significance:** Understanding GAG structure may lead to understanding its biosynthesis and biological functions.

Decorin proteoglycan is comprised of a core protein containing a single O-linked dermatan sulfate/chondroitin sulfate glycosaminoglycan (GAG) chain. Although the sequence of the decorin core protein is determined by the gene encoding its structure, the structure of its GAG chain is determined in the Golgi. The recent application of modern MS to bikunin, a far simpler chondroitin sulfate proteoglycans, suggests that it has a single or small number of defined sequences. On this basis, a similar approach to sequence the decorin of porcine skin much larger and more structurally complex dermatan sulfate/chondroitin sulfate GAG chain was undertaken. This approach resulted in information on the consistency/variability of its linkage region at the reducing end of the GAG chain, its iduronic acid-rich domain, glucuronic acid-rich domain, and non-reducing end. A general motif for the porcine skin decorin GAG chain was established. A single small decorin GAG chain was sequenced using MS/MS analysis. The data obtained in the study suggest that the decorin GAG chain has a small or a limited number of sequences.

Proteoglycans (PGs)<sup>2</sup> are biomolecular glycoconjugates comprised of one or more glycosaminoglycan (GAG) chains with a molecular weights in the range 5,000 to 40,000, covalently attached to a protein core (1). PGs make up a large proportion of the extracellular matrix, performing a variety of roles

in the excretory system, respiratory system, circulatory system, and skeletal system, and are involved in multisystem diseases of aging and cancer (2). The GAG chains of PGs are responsible for many of the biological functions of PGs, and subtle variations in the GAG structure can have pronounced effect on the organism physiology and pathophysiology (1, 3). Recent studies in our laboratory have focused on the application of MS, in combination with other analytical methods, to sequence (4) the chains of the small of biologically important small chondroitin sulfate (CS) PG, bikunin (5, 6), and small dermatan sulfate (DS) PG, decorin (7).

Decorin is one of the simplest cellular or pericellular matrix PGs belonging to the small leucine-rich proteoglycan family (8). Decorin consists of a protein core containing multiple leucine repeats with flanking cysteine-rich disulfide domains and a single CS or DS GAG chain. The GAG attachment site in human decorin is located near its N terminus (Ser-34), and several N-linked oligosaccharide attachment sites are located on Asn-211, Asn-262, and Asn-303 (9). Decorin has a high level of homology across mammalian species; for example, porcine and human decorin are ~90% homologous. Decorin GAG varies from CS-type (glucuronic acid (GlcA)-rich) to DS-type (iduronic acid (IdoA)-rich) depending on the tissue in which it is biosynthesized (2, 7, 10–12). In the endoplasmic reticulum, xylose is added to the Ser residue of the GAGylation site of the core protein, followed by the sequential addition of two galactose residues and glucuronate residue in the cis-Golgi (13–19). The resulting tetrasaccharide linker is extended through the action of glycosyltransferases and modified as it transits the Golgi by 4-O-sulfotransferase (four isoforms), 6-O-sulfotransferase (two isoforms), 2-O-sulfotransferase (one isoform), 4,6-O-sulfotransferase (one isoform), and C5-epimerase (two isoforms), which complete the decorin GAG biosynthesis (13–20). The disaccharide composition of the resulting CS/DS GAG chain is often determined through exhaustive treatment with chondroitin lyases (21). This results in disaccharides comprised of ΔUA (4-deoxy-α-L-threo-hex-4-enopyranosyl uronic acid) 1,3-linked to N-acetylgalactosamine that have eight distinct

\* This work was supported by National Institutes of Health Grants GM38060, HL096972, and ES 020903 (to R. J. L.) and by a grant from the China Scholarship Council (to X. Z.).

[5] This article contains supplemental Tables S1 and S2 and Figs. S1–S11.

<sup>1</sup> To whom correspondence should be addressed: Dept. of Chemistry and Chemical Biology, Ctr. for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Inst., Biotechnology Bldg. 4211, Troy, NY 12180. Tel.: 518-276-2927; Fax: 518-276-3405; E-mail: lil12@rpi.edu.

<sup>2</sup> The abbreviations used are: PG, proteoglycan; GAG, glycosaminoglycan; CS, chondroitin sulfate; DS, dermatan sulfate; GlcA, glucuronic acid; IdoA, iduronic acid; RE, reducing end; dp, degree of polymerization; NRE, non-reducing end; FT, Fourier-transform; SEC, size exclusion chromatography; TIC, total ion chromatogram; HILIC, hydrophilic interaction liquid chromatography.

sulfation patterns, 0S, 2S, 4S, 6S, 2S4S, 2S6S, 4S6S, and 2S4S6S (22).

Decorin is particularly rich in tissues such as skin (23, 24), tendons (25, 26), and cornea (27) where it plays a critical role in decorating or organizing collagen fibrils (28, 29). Both the core protein and GAG chain play critical but distinct roles in fibrillar organization (25, 28). The role of the GAG chain is somewhat less clear as they lie on the surface of the fibrils perpendicular to their long axis and may inhibit the lateral interaction of fibrils, resisting compression and regulating fibril diameter (23, 28). GAG stiffness, related to the structure and content of AC/B-type domains (conformationally flexible IdoA residues (30) are present in B-type domains) may play a critical role in the biomechanical function of these tissues (23, 26, 28). Indeed, a genetic mutation of human galactosyltransferase-1, which reduces both the GAG chain occupancy in decorin and the IdoA content of decorin GAG, results in connective tissue disorders (24). Furthermore, C5-epimerase-1-deficient mice showed an altered distribution of IdoA, resulting in an altered collagen structure leading to skin fragility (19, 31).

In addition to its role in the proper assembly of collagen fibrils, fibrillogenesis (28, 29), decorin plays a role in interactions with cytokines and growth factors, such as TNF, and FGF-2. Growth factor receptors, such as epidermal growth factor receptor, insulin-like growth factor receptor 1, and hepatocyte growth factor receptor are also regulated by decorin (10, 31). Thus, decorin acts as a pan-tyrosine kinase receptor inhibitor (31) regulating cell growth, wound healing, angiogenesis, axon regeneration, and neural stem cell proliferation (10). Decorin acts as a “guardian for the matrix” in preventing tumor growth (32, 33). Although much of the activity of decorin is associated with its core protein (32), its CS/DS chain certainly also contributes to decorin biology (2, 34). Rare (<10%) and more highly sulfated GAG domains containing disulfated and potentially even trisulfated CS/DS disaccharides (19, 35, 36) represent structural features important in protein-GAG interactions (2). Decorin GAG may also inhibit blood coagulation through its interaction with von Willebrand factor (37) and heparin cofactor II (8, 34, 38).

A detailed knowledge of the decorin PG structure is necessary to fully understand its structure-function relationship (39). Although the sequence and the sites of post-translational modifications of decorin core protein have been determined (8) and its crystal structure has been solved (40), the GAG sequence analysis remains a challenge, in part due to the lack of sequencing tools capable of handling the tremendous structural complexity of this polysaccharide. Structural characterization of large complex polysaccharides such as decorin GAG relies on enzymology combined with an array of analytical techniques.

Recombinantly expressed decorins have been subjected to structural analysis (7, 13). CHO cell-expressed recombinant human decorin GAG chains have several linkage region hexasaccharides (arising from the reducing end (RE) of the chain), the majority containing the sequence  $\Delta\text{UA } \beta\text{1-3GalNAc } \beta\text{1-4GlcA } \beta\text{1-3Gal } \beta\text{1-3Gal } \beta\text{1-4Xyl/Xyl-ol}$  (where Gal is galactopyranose and Xyl/Xyl-ol are xylose and its  $\text{NaBH}_4$  reduced form xylitol), 12% of which were unsulfated and 60% contained GalNAc4S residue (13). The GAG chain was com-

prised of 88% 4S, 8% 0S, and 4% 2S4S (13). Domain analysis of human decorin from cultured fibroblasts showed it to be rich in 4S and 0S disaccharide units with small amounts of 2S4S located at the chains non-reducing end (NRE) (35, 36, 41). Domain mapping of HEK cell-expressed recombinant human decorin GAG chains, having a degree of polymerization (dp) of  $\sim 50$  disaccharide units with a 5:1 ratio GlcA:IdoA, showed a CS-type domain extending from its linkage region with extended B-type domains interspersed in the center of the chain and CS-type domain at the chains non-reducing end (NRE) (7). The disaccharide composition of the GAG was 63% 4S, 23% 6S, 12% 0S, 1% 2S6S, 1% 2S4S, and 0.4% 4S6S, with the 2S6S in the B-type domain and the 4S6S in the AC-type domain near the NRE (7).

In previous studies, we performed domain mapping, on the structurally simpler bikunin PG with a single CS GAG chain comprised of a linkage region and  $\sim 16$  disaccharides (0S and 4S and no IdoA), analyzing the composition of intact GAG chains using Fourier-transform (FT) MS analysis (5). Recently, FT-MS/MS has been used in a top-down approach to successfully determine the sequence of the intact bikunin CS GAG chains (6). In the current study, we have applied a similar domain mapping strategy to a much more structurally complex target, porcine skin decorin, and have used FT-MS and MS/MS to begin to elucidate the structure of its GAG chains.

## EXPERIMENTAL PROCEDURES

Actinase E (EC 3.4.24.4) was from Kaken Biochemicals (Tokyo, Japan). Chondroitin sulfate A was purchased from Celcus Laboratories (Cincinnati, OH). Recombinant human decorin PG was expressed as a polyhistidine fusion protein in a stably transfected HEK (human embryonic kidney) 293-EBNA cell line as described previously (42). Endolytic chondroitinase ABC from *Proteus vulgaris* (EC 4.2.2.20), endolytic chondroitinase AC-1 from *Flavobacterium heparinum* (EC 4.2.2.5), exolytic chondroitinase AC-2 from *Arthrobacter aureescens* (EC 4.2.2.5), endolytic chondroitinase B from *F. heparinum* (EC 4.2.2.x) (43, 44), and 4,5-unsaturated CS/DS disaccharide standards:  $\Delta\text{UA-GalNAc}$  (0S, where S is sulfo),  $\Delta\text{UA-GalNAc4S}$  (4S),  $\Delta\text{UA-GalNAc6S}$  (6S),  $\Delta\text{UA2S-GalNAc}$  (2S),  $\Delta\text{UA2S-GalNAc4S}$  (2S4S),  $\Delta\text{UA2S-GalNAc6S}$  (2S6S),  $\Delta\text{UA-GalNAc4S6S}$  (4S6S), and  $\Delta\text{UA2SGalNAc4S6S}$  (2S4S6S), were from Seikagaku (Associates of Cape Cod, East Falmouth, MA). Hyaluronic acid molecular weight standards were from Hyalose, L.L.C. (Oklahoma City, Oklahoma). Chondroitin sulfate C, [ $^2\text{H}$ ]H<sub>2</sub>O (99.996), urea, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, Alcian blue, and tributylamine were from Sigma. PMSF was from Sigma. Electrophoresis-grade acrylamide, *N,N'*-methylenebis(acrylamide), glycine, *N,N,N',N'*-tetramethylethylenediamine, ammonium persulfate, Tris, and Na<sub>2</sub>EDTA were from Bio-Rad. All solvents were HPLC grade.

*Purification of Decorin from Porcine Skin*—Porcine skin decorin was purified through the modification and scale-up of a procedure used to prepare human skin decorin (28). Porcine skin was obtained from a domestic slaughterhouse in Chiba Prefecture, Japan. Pieces of skin collected for GAG preparation were  $\sim 500$  g of wet weight. The tissue was washed free of blood

## Sequencing Decorin Glycosaminoglycan

in ice-cold isotonic saline before and after being pinned out, epidermal side down, on a Teflon board set into crushed ice. Fat was removed as quickly as possible, after which the surface of the skin was scraped with a solid metal scalpel, and the dermal material, containing most of the decorin, was placed in a clean preweighed 2-liter Erlenmeyer flask. The skin was horizontally scored into fine strips using a disposable blade scalpel, followed by slicing at a 90° angle to release thin slivers of skin. One liter of ice-cold water was added, and the material was swirled for 10 min; this process was repeated twice. This was followed by a similar operation with ice-cold 0.15 M saline before the skin material was collected on a wire mesh. Skin material was put into 1 liter of ice-cold 1 M NaCl to which 5 ml of freshly prepared saturated phenylmethylsulphonyl fluoride solution was added, and the flask was swirled at 4 °C for 18 h, with changes at 1 h and 3.5 h. The skin pieces were collected in a mesh and pressed to remove the salt solution before being placed in buffer (1 liter of 1 M sodium citrate at pH 3.5) to which PMSF had been added as above. The flask was swirled at 4 °C for 18 h, at which time the material was separated into solid and supernatant fractions by passing the preparation through a fine steel mesh. The solid residue was taken once again through a second and third extract. Supernatant collected above was put into five dialysis bags each containing almost 200 ml extract and dialyzed against three changes of 5 liters of water. The dialyzed extract was put through a 0.45-mm filter, set out in 200-ml aliquots in sterile containers; some were set aside for immediate analysis by gel electrophoresis, whereas the remainder was freeze-dried and retained as the decorin PG fraction (Fig. 1A).

**Preparation of Decorin GAG**—Decorin PG fraction (~100 mg) was treated with actinase E (1 g) in 500 ml (pH 8) sodium phosphate buffer at 55 °C for 10 h to afford decorin peptidoglycosaminoglycan. The GAG component of decorin was released by base-catalyzed  $\beta$ -elimination under reducing conditions. Decorin peptidoglycosaminoglycan was dissolved in a 0.2 M NaOH solution containing 1% NaBH<sub>4</sub>. The reaction was allowed to proceed overnight at 4 °C and neutralized with 1 M hydrochloric acid. The remaining peptides were precipitated by addition of 20% perchloric acid. The supernatant obtained by centrifuge at 1500  $\times$  g was collected and dialyzed against water for 16 h and freeze-dried, resulting in 50–60 mg of decorin GAG.

**<sup>1</sup>H-NMR Spectroscopy**—Decorin GAG (5 mg) was dissolved in 0.4 ml of [<sup>2</sup>H]H<sub>2</sub>O (99.96%), freeze-dried three times from [<sup>2</sup>H]H<sub>2</sub>O, and redissolved in 0.4 ml of [<sup>2</sup>H]H<sub>2</sub>O for one-dimensional NMR. NMR was recorded on a Bruker Avance II 600 MHz spectrometer equipped with a cryogenically cooled HCN probe with a z axis gradient. All NMR experiments were recorded at 40 °C (313 K). One-dimensional <sup>1</sup>H-NMR spectra were recorded with 128 scans with a spectral width of 12 kHz and an acquisition time set to 2.7 s.

**Size Exclusion Chromatography**—Size exclusion chromatography (SEC) was performed on decorin GAG (20  $\mu$ g) using TSK-GEL G4000PWxl SEC column with a sample injection volume of 20  $\mu$ l and a flow rate of 0.6 ml/min on an apparatus composed of a Shimadzu LC-10Ai pump, a Shimadzu CBM-20A controller, and a Shimadzu RID-10A refractive index detector. The mobile phase consisted of 0.1 M NaNO<sub>3</sub>. The

column was maintained at 40 °C with an Eppendorf column heater during the chromatography. The SEC chromatograms were recorded with the LCsolution software (version 1.25) and analyzed with its “GPC Postrun” function. For molecular weight determination, hyaluronic acid standards of different molecular weights (30,600, 43,800, 78,700, and 130,200) were used as calibrants for the standard curve.

**Disaccharide Analysis of Decorin GAG**—Decorin GAG (20  $\mu$ g) was dissolved in 1  $\mu$ l of 0.5 mM NH<sub>4</sub>HCO<sub>3</sub> solution and exhaustively treated with 30 milliunits of chondroitinase ABC and 30 milliunits of chondroitinase AC-2 by digesting at 37 °C for 10 h. The depolymerization reaction products were labeled by reductive amination with 2-aminoacridone (AMAC) and subjected to disaccharides analysis by LC-MS (22).

**Disaccharide Analysis by Reverse Phase HPLC-MS**—LC-MS analyses were performed on an Agilent 1200 LC/MSD instrument (Agilent Technologies, Inc., Wilmington, DE) equipped with a 6300 ion trap. The column used was a Poroshell 150 C18 column (2.1  $\times$  100 mm, EC-2.7  $\mu$ m, Agilent) at 45 °C. For dual ammonium acetate and methanol gradient, eluent A was 80 mM ammonium acetate solution, and eluent B was methanol. Solution A and 12% solution B was flowed (120  $\mu$ l/min) through the column for 15 min followed by linear gradients 12–15% solution B from 15 to 30 min, 15–30% solution B from 30 to 60 min, and 30–100% solution B from 60 to 62 min.

**Preparation of Decorin GAG Domains**—Decorin GAG (200  $\mu$ g) was exhaustively treated three times with 10 milliunits of chondroitinase AC-1 (endolyase) in 50 mM ammonium bicarbonate buffer (pH 8) at 37 °C for 10 h to obtain DS-type domains. Similarly, decorin GAG (200  $\mu$ g) was exhaustively treated three-times with or 2.5 milliunits of chondroitinase B (endolyase) in 50 mM ammonium bicarbonate buffer (pH 8) at 37 °C for 10 h to obtain AC-type domains. The B-type and AC-type domains were subjected to isocratic gel electrophoresis on a 15% acrylamide gel and disaccharides analysis by LC-MS. The B-type and AC-type domains were subjected to HILIC LC-MS on an Orbitrap spectrometer.

**PAGE Analysis**—Products of the decorin GAG enzymatic depolymerization were analyzed by native PAGE using 0.75 mm  $\times$  6.8 cm  $\times$  8.6 cm mini gels cast from 15% T resolving gel monomer solution and 5% T stacking gel monomer solution. Chondroitin sulfate A partially digested by chondroitinase ABC was used as molecular markers. The mini gels were subjected to electrophoresis at a constant 200 V for 30 min and visualized with 0.5% (w/v) Alcian blue in 2% (v/v) aqueous acetic acid solution. Molecular weight analysis was performed with the aid of UNSCANIT software (Silk Scientific) using the logarithmic relationship between the GAG molecular weight and its migration distance.

**Continuous Elution PAGE Fractionation of B-type Domains**—B-type domains (4 mg) were loaded on 15% preparative polyacrylamide gel and fractionated by continuous elution electrophoresis on a Model 491 Prep cell with a 28-mm internal diameter gel tube (Bio-Rad) (45). Electrode running buffer was 1 M glycine and 0.2 M Tris (pH 9 without adjustment), and the lower chamber and elution buffer chamber were filled with resolving buffer. A peristaltic pump was set to 1 ml/min. The gel was subjected to electrophoresis at a constant power of 12 watts for 6 h. The eluted fractions were collected in 1-ml tubes. After


being freeze-dried, each tube was dissolved in 100  $\mu$ l of water, and 5  $\mu$ l was loaded on an analytical 15% gel with 5  $\mu$ l of 50% sucrose for PAGE analysis.

**HILIC LC-FT-MS and MS/MS Characterization of Decorin Domain Structures**—LC separation and FT-MS analysis relied on similar conditions to those used for the analysis of intact chains of low molecular weight heparin (46, 47). Briefly, a Luna HILIC column (2.0  $\times$  150 mm, 200 A, Phenomenex, Torrance, CA) was used to separate the partially or fully digested decorin GAG. Mobile phase A was 5 mM ammonium acetate prepared with HPLC-grade water. Mobile B was 5 mM ammonium acetate prepared in 98% HPLC-grade acetonitrile with 2% of HPLC-grade water. After injection of 8.0  $\mu$ l of decorin GAG (1.0  $\mu$ g/ $\mu$ l) through an Agilent 1200 auto-sampler, HPLC binary pump was used to deliver the gradient from 10% A to 35% A for 40 min at a flow rate of 150  $\mu$ l/min. The LC column was directly connected online to the standard ESI source of LTQ-Orbitrap XL FT MS (Thermo Fisher Scientific). The source parameters for FT-MS detection were optimized using Arित्रा® to minimize the in-source fragmentation and sulfate loss and maximize the signal/noise in the negative ion mode. The optimized parameters, used to prevent in-source fragmentation, included a spray voltage of 4.2 kV, a capillary voltage of -40 V, a tube lens voltage of -50 V, a capillary temperature of 275  $^{\circ}$ C, a sheath flow rate of 30, and an auxiliary gas flow rate of 6. External calibration of mass spectra routinely produced a mass accuracy of better than 3 ppm. All FT mass spectra were acquired at a resolution 60,000 with a 400–2000 molecular weight range.

**Bioinformatics**—Charge deconvolution was either performed manually with electronic spreadsheets or auto-processed by DeconTools software (which can be accessed online on the Pacific Northwest National Laboratory website at omics.pnl.gov/software/). Reducing end and non-reducing end structural assignments were performed by automatic processing using GlycReSoft software (version 1.0) developed at the Boston University School of Medicine (47). For automatic processing, GlycReSoft parameters (version 1.0) were set as the following: minimum abundance, 1.0; minimum number of scans, 1; molecular weight lower boundary, 50,000; molecular weight upper boundary, 10,000; mass shift, ammonium; match error ( $E \pm M$ ), 5.0 ppm; grouping error ( $E \pm G$ ), 80 ppm; adduct tolerance ( $E \pm A$ ), 5.0 ppm. For reducing end (including linkage), middle chain, and non-reducing end oligosaccharide identification, theoretical database was generated by GlycReSoft (version 1.0) using the following parameters: A,  $\Delta$ HexA = 0 (non-reducing end), 1 (middle chain) or linker (Xyl-Gal-Gal-GlcA); B, HexA = 0 to 12; C, HexNAc = A + B - 1 to A + B + 1; D, Ac = 0; E,  $SO_3$  = B to A + B + (C  $\times$  2) + 1 - D; modification, adduct = ammonium from 0–5.

## RESULTS

From 500 g of wet porcine skin  $\sim$ 100 mg of decorin proteoglycans of high purity was obtained (Fig. 1A). Proteolysis with actinase E afforded decorin peptidoglycan which was converted to 50–60 mg of decorin GAGs by reductive  $\beta$ -elimination. One-dimensional  $^1$ H-NMR analysis confirmed the purity



**FIGURE 1. Intact decorin characterization.** A, analysis of porcine skin decorin by SDS-PAGE. The gel was stained with Alcian blue. B, SEC analysis of porcine skin decorin GAG. The column was calibrated using hyaluronan oligosaccharide standards of defined molecular weight. uRIU corresponds to micro-refractive index units. C,  $^1$ H-NMR analysis of porcine skin decorin GAG performed in  $D_2O$  at 800 MHz. The ratio of the IdoA-H1 and GlcA-H1 were calculated as 3:1.


the porcine skin decorin GAG to be  $>90\%$  (see Fig. 1C). The  $^1$ H-NMR spectrum of the decorin GAG was next used to determine the ratio of GlcA to IdoA. Integration of the anomeric (H1) signals of IdoA and GlcA were observed at 4.95 and 4.55 ppm, respectively, afforded a 3:1 ratio of IdoA:GlcA.

Next, the molecular weight properties of porcine skin decorin GAG was analyzed using SEC (Fig. 1B). The values for decorin GAG weight average (molecular weight, 22,300) and number average ( $M_n$ , 20,900) molecular weights were derived by extrapolating the linear standard curve obtained using the available hyaluronan standards log (molecular weight) as a function of elution time (using  $y = 0.252 \times + 7.66$ ,  $r^2 = 0.999$ ). This corresponds to an average chain length of 46 disaccharides (based on the one-sulfate/disaccharide repeating unit of 459) and a range of chain sizes from 16 disaccharides (7,100) to 98 disaccharides (44,800) with dispersity ( $M_w/M_n = 1.07$ ).

ESI-FT-MS was next used to examine intact decorin GAG chains using the same approach that had been successful for the analysis of the less highly sulfated and much smaller bikunin CS GAG chains (6). GAG chains were first fractionated by preparative continuous elution PAGE (data not shown) and then analyzed by ESI-FT-MS. This approach had limited success providing molecular weight data on the smaller ( $dp < 42$ ) decorin GAG chains. All of the intact chains analyzed by ESI-FT-MS contained a mass signature consistent with the presence of linkage region terminated with xylitol at the reducing end and most contained an odd number of saccharide units consistent with a GalNAc residue at the NRE of the chain.

Disaccharide analysis was next performed on porcine skin decorin GAG following exhaustive depolymerization with chondroitinase ABC and AC-2 using LC-MS analysis (supplemental Fig. S1 and supplemental Table S2). The disaccharide composition of porcine skin decorin GAG showed the expected major was 4S (87.3%) with additional minor disaccharides including: 6S (5.5%), 0S (5%), and 2S4S (2.2%).

## Sequencing Decorin Glycosaminoglycan



**FIGURE 2. Domain mapping of decorin.** *Inset*, PAGE (15% acrylamide) analysis of chondroitinase-treated decorin GAGs. *Lane 1*, chondroitin sulfate A standard (*Std*) partially (~30% completion) treated with chondroitinase AC-1 with oligosaccharide size dp6 through dp38 labeled on the *left*; *lane 2*, AC-type domains prepared by chondroitinase B-treatment of porcine skin decorin GAG. *Lane 3*, B-type domains prepared by chondroitinase AC1-treatment of porcine skin decorin GAG. *Lane 4*, AC-type domains prepared by chondroitinase B-treatment of HEK cell decorin GAG; *lane 5*, B-type domains prepared by chondroitinase AC1-treatment of HEK cell decorin GAG. The PAGE-gel analysis of porcine skin decorin (*lanes 2 and 3*) was next digitized by UN-SCAN-IT, and the oligosaccharide composition was calculated. *A*, the WT % composition of porcine skin decorin GAG is shown with the AC1-type domains (*open bars*) and the B-type domains (*filled bars*). *B*, the mol % composition of porcine skin decorin GAG is shown with the AC1-type domains (*open bars*) and the B-type domains (*filled bars*).

Domain mapping with a partial digestion approach was next undertaken by treating porcine skin decorin GAG with chondroitinase ABC ([supplemental Fig. S2](#)), by chondroitinase AC-1 (cutting AC-domains) to afford B-type domains ([supplemental Fig. S3](#)) or by chondroitinase B (cutting B-domains) to afford AC-type domains ([supplemental Fig. S4](#)).  $^1\text{H-NMR}$  had shown a 3:1 ratio IdoA:GlcA (see [Fig. 1C](#)), corresponding to a 3:1 ratio

of B-type:AC-type domains. Domain mapping involving exhaustive digestion by chondroitinase B or by chondroitinase AC-1, followed by PAGE analysis, was performed on porcine skin decorin ([Fig. 2, inset, lanes 2 and 3](#)) to visualize the AC-type and B-type domains, respectively. In contrast, domain mapping of recombinant human decorin, prepared in HEK cells and previously studied in our laboratory (7), shows quite different dis-




FIGURE 3. TIC of HILIC LC-MS analysis of porcine skin decorin GAG domains (shaded area are oligosaccharides from linkage domains). A, chondroitinase ABC treatment to afford AC-type and B-type domains products (see supplemental Table S2) and intact linkage regions; B, chondroitinase B treatment to afford B-type domain products (see supplemental Table S2) and intact AC-type domains and linkage regions; and C, chondroitinase AC-1 treatment to afford AC-type domain products (see supplemental Table S2) and intact B-type domains and linkage regions.

tributions of AC-type and B-type domains (lanes 4 and 5 in Fig. 2, inset). Quantification of the AC-type and B-type domain was performed by integrating the gel band intensities in Fig. 2 and plotting as weight and mole percentages as a function of chain size in dp (Fig. 2, A and B). Disaccharide analysis of AC-type domains was mainly composed of 4S (89.8%) with minor amounts of 2S4S (10.2%), and the B-type domain was composed only of 4S (79.9%) with minor amounts of 6S (12.1%) and 0S (8%) (supplemental Table S2). The B-domains were fractionated by preparative continuous PAGE, and domains ranging from dp6 to dp40 were collected.

HILIC LS-MS was next applied to analyze the domain structure present at the RE of decorin GAG chains. Digestion with chondroitinase ABC (see supplemental Fig. S2 for digestion kinetics) converted the AC-type and B-type domains into disaccharide and tetrasaccharide products and afforded intact linkage region as hexasaccharides (Fig. 3A). Digestion with chondroitinase B (see supplemental Fig. S4 for digestion kinetics) converted the B-type domain primarily into disaccharide products and afforded intact AC-type domains of dp6–dp22 and linkage regions distributed through these fractions (Fig. 3B). Digestion with chondroitinase AC1 (see supplemental Fig. S3 for digestion kinetics) converted the AC-type domain into disaccharide products (see supplemental Table S2) and

afforded intact B-type domains of dp6–dp40 and dp4 linkage regions (Fig. 3C).

Next, our attention turned to understanding the structural diversity of the linkage regions prepared from porcine skin decorin. MS analysis of porcine skin decorin GAG exhaustively digested with chondroitinase ABC showed multiple hexasaccharides containing linkage region (Fig. 3A, shaded peaks). Using HILIC, five hexasaccharides were obtained and separated by HILIC chromatography. Their composition was determined from their accurate masses observed in FT MS analysis (mass accuracy within 5 ppm) (Fig. 4A). Sequencing by MS/MS showed that these hexasaccharides each contained a linkage region tetrasaccharide at their RE coupled to a near-linkage region disaccharide (Figs. 4C and supplemental Figs. S5–S7). The three most abundant hexasaccharides (linker-1, -2, and -3) representing ~90% of the linkage region contained xylitol residues (corresponding to Xyl) at their RE. The two minor hexasaccharides (linker-4 and -5) had a xylitol-P residues (corresponding to Xyl-2-phosphate) at their RE (Fig. 4).

The data presented on the oligosaccharide distribution presented in Figs. 3 and 4 are based on total ion chromatogram (TIC) and are only semi-quantitative because of differences in ionization efficiencies of oligosaccharides of different size and charge. We next normalized the integrated values for UV-de-

## Sequencing Decorin Glycosaminoglycan




FIGURE 4. **HILIC LC-MS analysis of porcine skin decorin linkage region.** *A*, extracted ion chromatography (mass accuracy within 5 ppm) showing HILIC separation, integration, and structures of the five linkage regions. Accurate mass can distinguish phosphorylation (monoisotopic mass, 79.96633 Da) from sulfation (monoisotopic mass, 79.95682 Da). *B*, relative abundance of the five linkage regions. *C*, FT MS/MS fragments example of linker-4 to confirm the phosphate location.

tected peaks (at 232 nm) to TIC peaks to obtain a more quantitative interpretation of the structure of porcine skin decorin GAG. Oligosaccharides from dp4 to dp20, prepared by partial chondroitinase AC-1 treatment of chondroitin sulfate A, were fractionated by BioGel P-10 column with UV detection and used as standards. In this way HILIC-LC-MS TIC peak areas could be correlated to their UV peak areas and their corresponding to molar concentrations (supplemental Fig. S8). These correction factors were then used to quantify oligosaccharides measured in the TIC. Oligosaccharides from dp2–12 gave comparable TIC response, whereas higher oligosaccharides, dp14–18 and above, required increasingly larger correction factors (supplemental Fig. S9). Using these correction factors the relative abundance could be estimated of oligosac-

charides arising from the RE (containing the linkage region) and the NRE (containing a terminal *N*-acetylgalactosamine or saturated uronic acid residue) (Fig. 5). In Fig. 5A, the relative abundance of the different reducing ends clearly demonstrates that chondroitinase AC-1 generates primarily an unsulfated tetrasaccharide (dp4 + 0 sulfo groups) and chondroitinase ABC generates primarily three hexasaccharides (dp6 + 0, 1, or 2 sulfo groups) and chondroitinase B generates a range of larger oligosaccharides (dp6 to dp20) comprised of an unsulfated tetrasaccharide linkage region followed by one to eight monosulfated glucuronic acid-containing disaccharides. Oligosaccharides arising from the NRE of the porcine skin decorin GAG chain by treatment with the same chondroitinases were quantified using this method (Fig. 5B). Chondroitinase ABC releases




FIGURE 5. Normalized HILIC LC-MS data for the reducing ends (A) and non-reducing ends (B) of the porcine skin decorin GAG chains (insets indicate the major structure motif at the reducing end and non-reducing end). Blue bars correspond to chondroitinase ABC-treated, green bars correspond to chondroitinase AC-1-treated, and red bars correspond to chondroitinase B-treated.

only odd oligosaccharides, primarily a trisaccharides (with 1, 2 or 3 sulfo groups) and to a lesser degree pentasaccharides (with two, three, four, or five sulfo groups). Chondroitinase B releases primarily tetrasaccharide (with two sulfo groups), or pentasaccharide (with two, three, or four sulfo groups) and much lower amounts of dp5, dp7, dp9, dp11, and dp13 oligosaccharides. Chondroitinase AC1 releases nearly uniform amounts of both odd and even oligosaccharides ranging in size from dp3 to dp13. In summary, all three enzymes demonstrated a preference for

releasing of odd chains (ending in GalNAc) that were especially rich in B-type domains containing disulfated disaccharide units. A summary of these quantitative data can be found in Table 1.

Analysis of the internal domains was next undertaken. The AC-type domains account for ~25% of the chains by <sup>1</sup>H-NMR and ~32% of the chains by integration of the scanned PAGE data (Fig. 2B and inset). Based on HILIC LC-MS data on dp6–dp12 AC-type oligosaccharides, only ~30% of the AC-type

## Sequencing Decorin Glycosaminoglycan

**TABLE 1**

**Comparison of GAG chains from different decorin samples**

nr indicates not reported; avg. indicates average.

Property	Decorin sample			
	Porcine skin	HEK human recombinant (7)	CHO human recombinant (11)	Human fibroblast (31–33, 41,44)
Molecular weight	$M_r$ , 20,900 $M_w$ , 22,300	$M_r$ , 22,000 $M_w$ , 30,000	nr	nr
dp-high, low, average	296, 32, 92	nr, nr, 100	nr	nr
IdoA:GlcA	3:1	1:5	nr	1.5:1
Sulfation level	0.98S/di	0.9 S/di	nr	nr
Disaccharide composition	88% 4S, 5.5% 6S, 5% 0S, 2.2% 2S4S	63% 4S, 23% 6S, 12% 0S, 1% 2S6S, 1% 2S4S, 0.4% 4S6S	88% 4S, 8% 0S, 4% 2S4S	nr
Odd/even chains	4:1	nr	nr	nr
Motifs (avg.)				
Linkage regions	Three tetrasaccharides, major with Gal, minor with Gal4S, very minor with Xyl2P	nr	two tetrasaccharides, major with Gal, minor with Gal4S	nr
Near linkage region	One 4S or 0S AC-type disaccharide	nr	one 4S, 0S or 6S AC-type disaccharide	nr
RE domain	Two 4S AC-type disaccharides	seven 4S disaccharides AC-type, 4S6S possible	nr	AC-type disaccharides
Internal domain	30 4S or 0S B-type disaccharides	12 4S or 0S B-type disaccharides	nr	B-type disaccharides in blocks of $\geq 4$
NRE domain	Five 4S, two 6S, one 2S4S AC-type disaccharides	22 AC-type disaccharides, rich in 4S6S	nr	nr




FIGURE 6. FT-MS/MS analysis of a short decorin GAG chain (dp31 + 14S,  $M = 6903.13$ ,  $m/z = 626.547$  Da).

domains are internal with  $\sim 70\%$  of these domains containing the linkage region at the chains reducing end (supplemental Fig. S10). Thus, only  $\sim 10\%$  of the internal chain domains are AC-type domains. These AC-type domains are relatively small in length dp4–dp20. In contrast, the B-type domains are usually found in the middle of the chain and account for  $\sim 90\%$  of the internal chain

domain. These domains can be quite large and range from dp6 to dp40. The B-type domains consist almost entirely of di4S units as judged by FTMS (supplemental Fig. S11) and from disaccharide analysis (supplemental Table S2).

Finally, we selected a single small decorin GAG chain, with a molecular weight of 6903.130, prepared by preparative gel elec-



## Sequencing Decorin Glycosaminoglycan

saccharide residues, a common disulfated linkage region with no phosphate, a short AC-type domain adjacent to the linkage region, and a continuous B-type domain of repeating di4S composition terminated at the NRE with GalNAc4S. We anticipate that as longer decorin GAG chains are sequenced we will begin to see the appearance of additional AC-type domains at the NRE and IdoA-rich 4S6S disulfated disaccharides. Based on our successful sequencing of bikunin, we believe that there is an excellent chance that decorin contains an unique or a small number of sequence variants that have a well defined RE and extended NRE repeating domains of variable lengths. These data continue to suggest that GAGs have a deterministic single or small number of sequences.

### REFERENCES

1. Heinegård, D. (2009) Proteoglycans and more—from molecules to biology. *Int. J. Exp. Pathol.* **90**, 575–586
2. Malavaki, C., Mizumoto, S., Karamanos, N., and Sugahara, K. (2008) Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. *Connect. Tissue Res.* **49**, 133–139
3. Iozzo, R. V., Zoeller, J. J., and Nystrom, A. (2009) Basement membrane proteoglycans: Modulators par excellence of cancer growth and angiogenesis. *Mol. Cell* **27**, 503–513
4. Li, L., Ly, M., and Linhardt, R. J. (2012) Proteoglycan Sequence. *Mol. Biosyst.* **8**, 1613–1625
5. Chi, L., Wolff, J. J., Laremore, T. N., Restaino, O. F., Xie, J., Schiraldi, C., Toida, T., Amster, I. J., and Linhardt, R. J. (2008) Structural analysis of bikunin glycosaminoglycan. *J. Am. Chem. Soc.* **130**, 2617–2625
6. Ly, M., Leach, F. E., 3rd, Laremore, T. N., Toida, T., Amster, I. J., and Linhardt, R. J. (2011) The proteoglycan bikunin has a defined sequence. *Nat. Chem. Biol.* **7**, 827–833
7. Laremore, T. N., Ly, M., Zhang, Z., Solakyildirim, K., McCallum, S. A., Owens, R. T., and Linhardt, R. J. (2010) Domain structure elucidation of human decorin glycosaminoglycans. *Biochem. J.* **431**, 199–205
8. Hocking, A. M., Shinomura, T., and McQuillan, D. J. (1998) Leucine-rich repeat glycoproteins of the extracellular matrix. *Matrix Biol.* **17**, 1–19
9. Seo, N. S., Hocking, A. M., Höök, M., and McQuillan, D. J. (2005) Decorin core protein secretion is regulated by N-linked oligosaccharide and glycosaminoglycan additions. *J. Biol. Chem.* **280**, 42774–42784
10. Seidler, D. G., and Dreier, R. (2008) Decorin and its galactosaminoglycan chain: extracellular regulator of cellular function? *IUBMB Life* **60**, 729–733
11. Nomura Y. (2006) Structural change in decorin with skin aging. *Connect. Tissue Res.* **47**, 249–255
12. Ruoslahti, E. (1988) Structure and biology of proteoglycans. *Annu. Rev. Cell Biol.* **4**, 229–255
13. Kitagawa, H., Oyama, M., Masayama, K., Yamaguchi, Y., and Sugahara, K. (1997) Structural variations in the glycosaminoglycan-protein linkage region of recombinant decorin expressed in Chinese hamster ovary cells. *Glycobiology* **7**, 1175–1180
14. Fransson, L. A., Belting, M., Jönsson, M., Mani, K., Moses, J., and Oldberg, A. (2000) Biosynthesis of decorin and glypican. *Matrix Biol.* **19**, 367–376
15. Silbert, J. E., and Sugumaran, G. (2002) Biosynthesis of chondroitin/dermatan sulfate. *IUBMB Life* **54**, 177–186
16. Prabhakar, V., and Sasisekharan, R. (2006) The biosynthesis and catabolism of galactosaminoglycans. *Adv. Pharmacol.* **53**, 69–115
17. Malmström, A., Bartolini, B., Thelin, M. A., Pacheco, B., and Maccarana, M. (2012) Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function. *J. Histochem. Cytochem.* **60**, 916–925
18. Maccarana, M., Olander, B., Malmström, J., Tiedemann, K., Aebersold, R., Lindahl, U., Li, J. P., and Malmström, A. (2006) Biosynthesis of dermatan sulfate: chondroitin-glucuronate C5-epimerase is identical to SART2. *J. Biol. Chem.* **281**, 11560–11568
19. Pacheco, B., Maccarana, M., and Malmström, A. (2009) Dermatan 4-O-sulfotransferase 1 is pivotal in the formation of iduronic acid blocks in dermatan sulfate. *Glycobiology* **19**, 1197–1203
20. Malmström, A., Bartolini, B., Thelin, M. A., Pacheco, B., and Maccarana, M. (2012) Iduronic acid in chondroitin/dermatan sulfate: biosynthesis and biological function. *J. Histochem. Cytochem.* [Epub ahead of print]
21. Gu, K., Linhardt, R. J., Laliberté, M., Gu, K., and Zimmermann, J. (1995) Purification, characterization and specificity of chondroitin lyases and glycuronidase from *Flavobacterium heparinum*. *Biochem. J.* **312**, 569–577
22. Solakyildirim, K., Zhang, Z., and Linhardt, R. J. (2010) Ultraperformance liquid chromatography with electrospray ionization ion trap mass spectrometry for chondroitin disaccharide analysis. *Anal. Biochem.* **397**, 24–28
23. Matsuda, N., Koyama, Y., Hosaka, Y., Ueda, H., Watanabe, T., Araya, T., Irie, S., and Takehana, K. (2006) Effects of ingestion of collagen peptide on collagen fibrils and glycosaminoglycans in the dermis. *J. Nutr. Sci. Vitaminol.* **52**, 211–215
24. Seidler, D. G., Faiyaz-Ul-Haque, M., Hansen, U., Yip, G. W., Zaidi, S. H., Teebi, A. S., Kiesel, L., and Götte, M. (2006) Defective glycosylation of decorin and biglycan, altered collagen structure, and abnormal phenotype of the skin fibroblasts of an Ehlers-Danlos syndrome patient carrying the novel Arg270Cys substitution in galactosyltransferase I ( $\beta$ 4GalT-7). *J. Mol. Med.* **84**, 583–594
25. Watanabe, T., Imamura, Y., Suzuki, D., Hosaka, Y., Ueda, H., Hiramatsu, K., and Takehana, K. (2012) Concerted and adaptive alignment of decorin dermatan sulfate filaments in the graded organization of collagen fibrils in the equine superficial digital flexor tendon. *J. Anat.* **220**, 156–163
26. Redaelli, A., Vesentini, S., Soncini, M., Vena, P., Mantero, S., and Montevicchi, F. M. (2003) Possible role of decorin glycosaminoglycans in fibril to fibril force transfer in relative mature tendons—a computational study from molecular to microstructural level. *J. Biomech.* **36**, 1555–1569
27. Zhang, Y., Conrad, A. H., and Conrad, G. W. (2011) Effects of ultraviolet-A and riboflavin on the interaction of collagen and proteoglycans during corneal cross-linking. *J. Biol. Chem.* **286**, 13011–13022
28. Wheatley, D. N., Graham, E., McMaster, R. S., Muir, I. F. K., Holmes, J. D., and Davies, M. (2004) Recovery of the decorin-enriched fraction, extract (D), from human skin: An accelerated protocol. *J. Biomed. Biotechnol.* **4**, 211–218
29. Reed, C. C., and Iozzo, R. V. (2002) The role of decorin in collagen fibrillogenesis and skin homeostasis. *Glycoconj. J.* **19**, 249–255
30. Ferro, D. R., Provasoli, A., Ragazzi, M., Casu, B., Torri, G., Bossennec, V., Perly, B., Sinaÿ, P., Petitou, M., and Choay, J. (1990) Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. *Carbohydr. Res.* **195**, 157–167
31. Maccarana, M., Kalamajski, S., Kongsgaard, M., Magnusson, S. P., Oldberg, A., and Malmström, A. (2009) Dermatan sulfate epimerase 1-deficient mice have reduced content and changed distribution of iduronic acids in dermatan sulfate and an altered collagen structure in skin. *Mol. Cell. Biol.* **29**, 5517–5528
32. Neill, T., Schaefer, L., and Iozzo, R. V. (2012) Decorin: a guardian from the matrix. *Am. J. Pathol.* **181**, 380–387
33. Buraschi, S., Neill, T., Owens, R. T., Iniguez, L. A., Purkins, G., Vadigepalli, R., Evans, B., Schaefer, L., Peiper, S. C., Wang, Z. X., and Iozzo, R. V. (2012) Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. *PLoS One* **7**, e45559
34. Linhardt, R. J., and Hileman, R. E. (1995) Dermatan sulfate as a potential therapeutic agent. *Gen. Pharmacol.* **26**, 443–451
35. Zamfir, A., Seidler, D. G., Kresse, H., and Peter-Katalinić, J. (2003) Structural investigation of chondroitin/dermatan sulfate oligosaccharides from human skin fibroblast decorin. *Glycobiology* **13**, 733–742
36. Seidler, D. G., Peter-Katalinić, J., and Zamfir, A. D. (2007) Galactosaminoglycan function and oligosaccharide structure determination. *ScientificWorldJournal* **7**, 233–241
37. Guidetti, G. F., Bartolini, B., Bernardi, B., Tira, M. E., Berndt, M. C., Balduini, C., and Torti, M. (2004) Binding of von Willebrand factor to the small proteoglycan decorin. *FEBS Lett.* **574**, 95–100
38. Tollefsen, D. M. (2010) Vascular dermatan sulfate and heparin cofactor II. *Prog. Mol. Biol. Transl. Sci.* **93**, 351–372
39. Seidler, D. G. (2012) The galactosaminoglycan-containing decorin and its impact on diseases. *Curr. Opin. Struct. Biol.* **22**, 578–582

40. McEwan, P. A., Scott, P. G., Bishop, P. N., and Bella, J. (2006) Structural correlations in the family of small leucine-rich repeat proteins and proteoglycans. *J. Struct. Biol.* **155**, 294–305
41. Zamfir, A. D., Flangea, C., Sisu, E., Serb, A. F., Dinca, N., Bruckner, P., and Seidler, D. G. (2009) Analysis of novel over- and under-sulfated glycosaminoglycan sequences by enzyme cleavage and multiple stage MS. *Proteomics* **9**, 3435–3444
42. Goldoni, S., Owens, R. T., McQuillan, D. J., Shriver, Z., Sasisekharan, R., Birk, D. E., Campbell, S., and Iozzo, R. V. (2004) Biologically active decorin is a monomer in solution. *J. Biol. Chem.* **279**, 6606–6612
43. Jandik, K. A., Gu, K., and Linhardt, R. J. (1994) Action pattern of polysaccharide lyases on glycosaminoglycans. *Glycobiology* **4**, 289–296
44. Gu, K., Liu, J., Pervin, A., and Linhardt, R. J. (1993) Comparison of the activity of two chondroitin AC lyases on dermatan sulfate. *Carbohydr. Res.* **244**, 369–377
45. Laremore, T. N., Ly, M., Solakyildirim, K., Zagorevski, D. V., and Linhardt, R. J. (2010) High-resolution preparative separation of glycosaminoglycan oligosaccharides by polyacrylamide gel electrophoresis. *Anal. Biochem.* **401**, 236–241
46. Ly, M., Wang, Z., Laremore, T. N., Zhang, F., Zhong, W., Pu, D., Zagorevski, D. V., Dordick, J. S., and Linhardt, R. J. (2011) Analysis of *E. coli* K5 capsular polysaccharide heparosan. *Anal. Bioanal. Chem.* **399**, 737–745
47. Li, L., Zhang, F., Zaia, J., and Linhardt, R. J. (2012) Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. *Anal. Chem.* **84**, 8822–8829